Media Advisory - Filomena Tassi to speak at McMaster University
HAMILTON, ON, Jan. 23, 2018 /CNW/ - Filomena Tassi, Member of Parliament for Hamilton West-Ancaster-Dundas, will be in Hamilton on January 24 to tour a lab at McMaster University, meet researchers, and announce a major investment in health research.
Media is invited to join the lab tour, to be followed by a funding announcement with media availability.
Date: January 24, 2018
Time: Lab tour 11:00 a.m.
Location: Health Sciences Centre (HSC-4N71) McMaster University 1200 Main Street Hamilton, Ontario ON L8S 4L8
Time: Announcement 11:30 a.m.
Location: Michael G. DeGroote Centre for learning and Discovery (MDCL-3023) McMaster University 1200 Main Street Hamilton, Ontario ON L8S 4L8
PureTech Health plc ("PureTech" or the "Company") today announces its results for the year ended December 31, 2023, as well as its cash balance as of the first quarter ended March 31, 2024. The following information represents select highlights from...
Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CHINA, HONG KONG, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR...
The Balance RehabClinic, renowned for its luxury mental health and addiction services, proudly announces its expansion into The Balance Healthcare Group: a collection of premium mental health solutions tailored for affluent individuals. These new...
Zest Dental Solutions, a global leader in innovative dental solutions proudly announces a strategic partnership with The Pathway. Founded by Justin Moody, DDS and based in Arizona, The Pathway is a continuing education program that teaches dentists...
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...
